Disc Medicine CEO granted RSUs and stock options

Disc Medicine, Inc. chief executive officer and director John D. Quisel reported equity awards consisting of restricted stock units and stock options.

Rhea-AI Filing Summary

Disc Medicine, Inc. chief executive officer and director John D. Quisel reported equity awards consisting of restricted stock units and stock options. On February 10, 2026, he received 55,200 shares of common stock in the form of RSUs at a grant price of $0, bringing his directly held common shares to 239,328.

On the same date, he was granted a stock option for 82,800 shares of common stock at an exercise price of $74.75 per share, expiring on February 9, 2036. The RSUs vest in four equal 25% annual installments starting February 15, 2027, while the option vests in 48 equal monthly installments beginning March 10, 2026, in each case subject to his continued service.

Insider Trade Summary

Grant/Award: 138,000 shares

Grant/Award 2 txns

Insider Quisel John D

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	82,800	$0.00	$0.00
Grant/Award	Common Stock	55,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 82,800 contracts (Direct); Common Stock — 239,328 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.
2. F2. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IRON CEO John D. Quisel report?

John D. Quisel reported equity awards, not open-market trades. He received 55,200 restricted stock units and a stock option for 82,800 shares, both granted on February 10, 2026, as part of his compensation with Disc Medicine, Inc.

How many Disc Medicine (IRON) RSUs were granted to the CEO?

The CEO received 55,200 restricted stock units. Each RSU represents a contingent right to one share of common stock and vests in four annual 25% installments starting February 15, 2027, contingent on his continued service with Disc Medicine, Inc.

What are the terms of the IRON stock options granted to the CEO?

The stock option covers 82,800 shares of common stock at a $74.75 exercise price. It vests in 48 equal monthly installments beginning March 10, 2026, and expires February 9, 2036, assuming John D. Quisel continues in service through each vesting date.

How many Disc Medicine (IRON) common shares does the CEO own after this Form 4?

Following the reported grant, John D. Quisel directly beneficially owns 239,328 shares of Disc Medicine common stock. This figure reflects his holdings after receiving 55,200 RSUs granted on February 10, 2026, as disclosed in the insider transaction report.

Is the IRON Form 4 transaction a stock purchase or a compensation grant?

The transactions are compensation grants, not market purchases. The Form 4 uses code “A” for grant, award, or other acquisition, with both the 55,200 RSUs and the 82,800 stock options granted at a price of $0 to the reporting person.

When will the IRON CEO’s RSUs and options fully vest if service continues?

RSUs vest in four annual tranches starting February 15, 2027, so they complete after the fourth installment. The options vest monthly over 48 months beginning March 10, 2026, and would be fully vested after those 48 monthly vesting dates, assuming continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 07:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quisel John D

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		55,200(1)	A	$0	239,328	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$74.75	02/10/2026		A		82,800		(2)	02/09/2036	Common Stock	82,800	$0	82,800	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.